FDA Approves First Recombinant von Willebrand Factor to Treat Bleeding Episodes

Molecular and Cellular Pharmacology, Vol 7, No 3 (2015)

FDA Approves First Recombinant von Willebrand Factor to Treat Bleeding Episodes

FDA News Release

Abstract

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD…..(click PDF to read more)

Full Text: PDF

LumiText Publishing, P.O. Box 774, Ellicott City, MD 21041